Dewei Jiang

Prof. Dr. Dewei Jiang

Department of Cancer Biology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WLWenjing Liu
Wenjing Liu
XLXiaoqing Lu
Xiaoqing Lu
PSPeiguo Shi
Peiguo Shi
GYGuangxi Yang
Guangxi Yang
ZZZhongmei Zhou
Zhongmei Zhou
Ceshi ChenCeshi Chen
Ceshi Chen
Breast cancer patients often suffer from disease relapse and metastasis due to the presence of breast cancer stem-like cells (BCSCs). Numerous studies have reported that high levels of inflammatory factors, including tumor necrosis factor alpha (TNF-α), promote BCSCs. However, the mechanism by which TNF-α promotes BCSCs is unclear. In this study, we demonstrate that TNF-α up-regulates TAZ, a transcriptional co-activator promoting BCSC self-renewal capacity in human breast cancer cell lines. Depletion of TAZ abrogated the increase in BCSCs mediated by TNF-α. TAZ is induced by TNF-α through the non-canonical NF-κB pathway, and our findings suggest that TAZ plays a crucial role in inflammatory factor–promoted breast cancer stemness and could serve as a promising therapeutic target.

4 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
QYQiyan Yin
Qiyan Yin
MZMin Zheng
Min Zheng
QLQianmei Luo
Qianmei Luo
Dewei JiangDewei Jiang
Dewei Jiang
HZHuifeng Zhang
Huifeng Zhang
Ceshi ChenCeshi Chen
Ceshi Chen
Y box binding protein 1 (YB-1) is a protein with a highly conserved cold shock domain (CSD) that also belongs to the family of DNA- and RNA-binding proteins. YB-1 is present in both the nucleus and cytoplasm and plays versatile roles in gene transcription, RNA splicing, DNA damage repair, cell cycle progression, and immunity. Cumulative evidence suggests that YB-1 promotes the progression of multiple tumor types and serves as a potential tumor biomarker and therapeutic target. This review comprehensively summarizes the emerging functions, mechanisms, and regulation of YB-1 in cancers, and further discusses targeted strategies.

13 January 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
Dewei JiangDewei Jiang
Dewei Jiang
TQTing Qiu
Ting Qiu
JPJunjiang Peng
Junjiang Peng
SLSiyuan Li
Siyuan Li
TATala
Tala
Ceshi ChenCeshi Chen
Ceshi Chen

10 May 2021 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
XWXinye Wang
Xinye Wang
TQTing Qiu
Ting Qiu
YWYingying Wu
Yingying Wu
CYChuanyu Yang
Chuanyu Yang
YLYi Li
Yi Li
Ceshi ChenCeshi Chen
Ceshi Chen

23 December 2022 in Advanced Science
Verified
Journal Article
Open access
WLWenjing Liu
Wenjing Liu
MZMin Zheng
Min Zheng
RZRou Zhang
Rou Zhang
QJQiuyun Jiang
Qiuyun Jiang
GDGuangshi Du
Guangshi Du
Ceshi ChenCeshi Chen
Ceshi Chen
Triple‐negative breast cancer (TNBC) has higher molecular heterogeneity and metastatic potential and the poorest prognosis. Because of limited therapeutics against TNBC, irradiation (IR) therapy is still a common treatment option for patients with lymph nodes or brain metastasis. Thus, it is urgent to develop strategies to enhance the sensitivity of TNBC tumors to low‐dose IR. Here, the authors report that E3 ubiquitin ligase Ring finger protein 126 (RNF126) is important for IR‐induced ATR‐CHK1 pathway activation to enhance DNA damage repair (DDR). Mechanistically, RNF126 physically associates with the MRE11‐RAD50‐NBS1 (MRN) complex and ubiquitinates MRE11 at K339 and K480 to increase its DNA exonuclease activity, subsequent RPA binding, and ATR phosphorylation, promoting sustained DDR in a homologous recombination repair‐prone manner. Accordingly, depletion of RNF126 leads to increased genomic instability and radiation sensitivity in both TNBC cells and mice. Furthermore, it is found that RNF126 expression is induced by IR activating the HER2‐AKT‐NF‐κB pathway and targeting RNF126 expression with dihydroartemisinin significantly improves the sensitivity of TNBC tumors in the brain to IR treatment in vivo. Together, these results reveal that RNF126‐mediated MRE11 ubiquitination is a critical regulator of the DDR, which provides a promising target for improving the sensitivity of TNBC to radiotherapy.

3 August 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
FLFubing Li
Fubing Li
HLHuichun Liang
Huichun Liang
HYHua You
Hua You
JXJi Xiao
Ji Xiao
HXHoujun Xia
Houjun Xia
Ceshi ChenCeshi Chen
Ceshi Chen
Metastasis is the leading cause of cancer-related death. The interactions between circulating tumor cells and endothelial adhesion molecules in distant organs is a key step during extravasation in hematogenous metastasis. Surgery is a common intervention for most primary solid tumors. However, surgical trauma-related systemic inflammation facilitates distant tumor metastasis by increasing the spread and adhesion of tumor cells to vascular endothelial cells (ECs). Currently, there are no effective interventions to prevent distant metastasis. Here, we show that HECTD3 deficiency in ECs significantly reduces tumor metastasis in multiple mouse models. HECTD3 depletion downregulates expression of adhesion molecules, such as VCAM-1, ICAM-1 and E-selectin, in mouse primary ECs and HUVECs stimulated by inflammatory factors and inhibits adhesion of tumor cells to ECs both in vitro and in vivo. We demonstrate that HECTD3 promotes stabilization, nuclear localization and kinase activity of IKKα by ubiquitinating IKKα with K27- and K63-linked polyubiquitin chains at K296, increasing phosphorylation of histone H3 to promote NF-κB target gene transcription. Knockout of HECTD3 in endothelium significantly inhibits tumor cells lung colonization, while conditional knockin promotes that. IKKα kinase inhibitors prevented LPS-induced pulmonary metastasis. These findings reveal the promotional role of the HECTD3-IKKα axis in tumor hematogenous metastasis and provide a potential strategy for tumor metastasis prevention.